search

Active clinical trials for "Tardive Dyskinesia"

Results 21-30 of 49

Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia

Tardive Dyskinesia

The purpose of this study is to assess the safety and efficacy of three doses (12.5, 25, and 50 mg) of NBI-98854 for the treatment of the symptoms of tardive dyskinesia (TD) in subjects with schizophrenia or schizoaffective disorder.

Completed14 enrollment criteria

Melatonin Treatment for Tardive Dyskinesia in Schizophrenia

Tardive Dyskinesia

This is a double-blind, randomized, placebo-controlled trial of melatonin as an add-on therapy to antipsychotics will be performed to examine the effects of melatonin on tardive dyskinesia symptoms and cognitive deficits in 120 patients with established tardive dyskinesia (TD). This study addresses a free radical hypothesis of TD.

Completed10 enrollment criteria

Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia...

Neuroleptic-Induced Tardive Dyskinesia

We initiate a study with research grant from department of health and Taoyuan mental hospital and choose risperidone and olanzapine as study medications. We compare the effects of these 2 drugs in schizophrenic spectrum patients of Han ethnics with neuroleptic-induced tardive dyskinesia to test the hypothesis that these two medications have different effects in improving tardive dyskinesia.

Completed9 enrollment criteria

Levetiracetam Treatment of Tardive Dyskinesia

Tardive Dyskinesia

This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.

Completed1 enrollment criteria

Treatment of Tardive Dyskinesia With Galantamine

Tardive Dyskinesia

Tardive dyskinesia (TD), a form of movement disorder, remains a problem for some patients who received antipsychotic medications. Increasing evidence suggests that TD may result from antipsychotic-induced dysfunction in striatal cholinergic neurons. To test whether cholinesterase inhibitors compensate for diminished cholinergic activity underlying TD, we conducted a 30-week randomized, double-blind, placebo-controlled crossover study of galantamine in 36 patients with TD.

Completed8 enrollment criteria

Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia

DyskinesiaSchizophrenia

Tardive dyskinesia is a common complication of conventional antipsychotic treatment in subjects with schizophrenia. This study investigates whether the addition of the omega-3 fatty acid, ethyl-eicosapentaenoic acid (EPA) to usual treatment improves movement disorder in 84 schizophrenia subjects with established tardive dyskinesia. The initial double-blinded, randomised trial duration is 12 weeks, followed by further 46 weeks of open-label treatment.

Completed12 enrollment criteria

Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia

Tardive Dyskinesia

The purpose of this study is to evaluate the efficacy and safety of MT-5199 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.

Completed8 enrollment criteria

Addressing Involuntary Movements in Tardive Dyskinesia

Tardive Dyskinesia

The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.

Completed19 enrollment criteria

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective...

Tardive Dyskinesia

The purpose of this study is to evaluate the efficacy, safety, and tolerability of two doses (12.5 and 50 mg) of NBI-98854 administered once daily (q.d.) for the treatment of tardive dyskinesia in subjects with schizophrenia or schizoaffective disorder.

Completed20 enrollment criteria

The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

Tardive Dyskinesia (TD)

This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the potential for clinical dependence and withdrawal symptoms associated with valbenazine.

Completed18 enrollment criteria

Need Help? Contact our team!


We'll reach out to this number within 24 hrs